查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098362

乳糜瀉治療市場 - 全球市場預測 2026-2032

Celiac Disease Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳糜瀉治療市場將成長至 25.7 億美元，複合年成長率為 10.33%。

主要市場統計數據
基準年 2025 12.9億美元
預計年份：2026年 14.2億美元
預測年份 2032 25.7億美元
複合年成長率 (%) 10.33%

隨著終身無麩質飲食的限制日益凸顯，乳糜瀉的治療正成為重要的治療方向。乳糜瀉是一種自體免疫腸道疾病，由具有遺傳易感性的個體攝取麩質引發。若治療不當，會導致腸道發炎、絨毛萎縮、吸收不良和全身性併發症。儘管嚴格的飲食限制仍然是標準治療方法，但日常生活中隱性攝取麩質、依從性差異、持續存在的症狀以及難治性乳糜瀉的存在，都使得藥物治療成為臨床上迫切的難題。藥物研發的重點在於降低麩質免疫抗原性、抑制免疫活化、保護腸道屏障、調節發炎路徑或誘導免疫耐受性等機制。關鍵的治療方法包括口服麩質酶、轉谷氨醯胺酶2抑制劑、緊密連接調節劑、細胞激素標靶藥物和抗原特異性免疫療法。臨床格局的形成受到血清學檢測技術的進步、醫生認知水平的提高以及對非飲食相關疾病負擔（例如貧血、骨質疏鬆、不孕、神經系統症狀和生活品質下降）認知的不斷加深的影響。檢驗的終點指標，包括組織學檢查觀察、症狀評分、麩質激發試驗模型和基於生物標記的患者分層，也在推動監管和臨床進展。隨著乳糜瀉治療方案的不斷發展，相關人員優先考慮安全性、長期耐受性、兒童適用性以及與飲食療法的兼容性。該領域的研究重點正從症狀控制轉向緩解疾病和暴露預防策略，旨在滿足持續性麩質敏感、意外攝入麩質或對飲食療法反應不佳的患者未被滿足的需求。

乳糜瀉治療領域發生變革性變化。

乳糜瀉的藥物治療模式正在重塑，治療方式正從單純的飲食管理轉向標靶藥物介入。雖然傳統上無麩質飲食是唯一可行的治療方法，但臨床證據表明，即使患者聲稱嚴格遵守飲食，仍會出現持續的腸道損傷和症狀。這通常是由於交叉污染、隱性麩質或麩質清除不徹底造成的。因此，人們更加關注輔助性治療，這些療法能夠在不取代嚴格飲食控制的情況下減輕黏膜損傷並改善日常疾病管理。另一個變革性的轉變是從廣泛的抗發炎概念轉向專注於特定作用機制的藥物設計。研發人員越來越關注轉谷氨醯胺酶2抑制劑，以抑制麩質胜肽的脫醯胺作用；在免疫活化前進行麩質的酵素解毒；以及調節腸道滲透性以減少抗原通過。免疫學驅動的創新，例如旨在重新訓練麩質特異性免疫反應和抑制T細胞主導的療法，也日益受到重視。臨床研發正日益以患者為中心，重點關注症狀負擔、偶然接觸麩質的情況、組織學癒合、血清學反應以及生活品質的可衡量改善。診斷技術的進步也影響著治療路徑，血清學篩檢、HLA-DQ2 和 HLA-DQ8 關聯檢測、內視鏡確診以及生物標記研究能夠更準確地識別合格的患者。同時，由於許多患者可能需要長期或反覆治療，監管機構和臨床醫生要求提供強力的安全性證據。這些變化正在將乳糜瀉治療確立為輔助性、預防性和潛在的緩解疾病方案，並將其納入更廣泛的自體免疫胃腸道疾病治療模式中。

人工智慧對乳糜瀉藥物研發的累積影響

人工智慧 (AI) 正在影響乳糜瀉藥物的發現、臨床試驗設計、患者分層以及真實世界臨床實踐中的疾病管理。在早期研究中，AI 驅動的蛋白質建模、免疫體學分析和電腦篩檢有助於識別與乳糜瀉病理生理學相關的麩質表位、候選酶、小分子抑製劑和免疫調節目標。機器學習模型在解讀來自基因組學、轉錄組學、微生物組學、血清學、組織病理學和患者報告結局 (PRO) 的複雜資料集方面正變得越來越有用，從而能夠更準確地了解疾病的異質性。在臨床開發中，AI 可以透過識別具有持續症狀、明確診斷、遺傳易感性或活動性黏膜損傷證據的患者來提高試驗可行性，從而支持患者選擇策略並降低變異性。數位工具還可以輔助遠端症狀追蹤、飲食攝取評估、治療依從性監測以及檢測與偶然攝取麩質相關的模式。人工智慧驅動的病理診斷可望標準化絨毛高度、隱窩深度和上皮內淋巴細胞的評估，從而提高組織學終點的一致性。利用自然語言處理技術，可以從電子健康記錄中提取信息，識別漏診患者、延遲診斷模式、合併自體免疫疾病以及醫療服務缺口。然而，其應用需要臨床檢驗的演算法、透明的資料管治、減少偏差以及遵守隱私法規。因此，人工智慧的累積影響不僅限於加快檢測速度，還包括擴展乳糜瀉個人化治療所需的證據基礎、提高臨床試驗效率以及改善治療反應的長期監測。

關於引進乳糜瀉治療的關鍵區域見解

在北美，乳糜瀉藥物的研發受益於許多因素，例如先進的胃腸病學診療路徑、對自體免疫胃腸道疾病的高度認知、組織轉谷氨醯胺酶IgA檢測的廣泛應用、活躍的臨床試驗體係以及強大的患者權益倡導組織對輔助療法的需求。美國和加拿大在應對意外接觸麩質和持續性症狀的治療方面準備較為充分，尤其是在通過標準化血清學檢測、必要時的十二指腸切片檢查以及專科會診確診的情況下。歐洲仍然具有影響力，這得益於其完善的乳糜瀉臨床指南、無麩質飲食標準的廣泛應用、免疫學和胃腸病學領域強大的學術研究以及針對慢性病治療的系統性監管要求。儘管西歐和南歐國家已建立成熟的診斷網路，但保險報銷、對無麩質食品的支持以及營養服務方面的區域差異仍然影響著患者的就醫途徑。在亞太地區，中國、印度、日本、韓國、澳洲和東南亞國協的認知度和診斷率都在提高，凸顯了乳糜瀉日益成長的重要性。該地區呈現出不同的臨床趨勢，包括亞洲部分地區歷來較低的診斷率、小麥消費模式的改變、專科醫療保健的擴展以及診斷檢測的日益普及。在拉丁美洲，尤其是在巴西和墨西哥，由於胃腸病學服務的擴展和公眾對麩質相關疾病認知的提高，人們對乳糜瀉的認知度正在提高，儘管不同醫療保健系統在獲得專科診斷和確診檢測方面存在差異。中東是一個重要的新興地區，這得益於海灣合作理事會（GCC）成員國醫療保健系統對自體免疫疾病的認知不斷提高，以及對專科診斷、三級醫療和先進治療的投入。雖然非洲的診斷率仍然相對較低，但都市區血清學檢測的普及、醫療保健系統的擴展以及對自體免疫胃腸道疾病認知的提高，正在幫助識別可能受益於未來藥物治療的患者。

針對特定族群的關鍵見解，有助於制定乳糜瀉藥物策略

在東協地區，乳糜瀉治療的重要性與診斷能力的提升、私人醫療網路的擴張以及人們日益認知到麩質相關自體免疫疾病在飲食模式改變的人群中可能存在漏診密切相關。未來治療方案的引入將取決於醫生的教育程度、檢測設施的可及性、註冊營養師的配備以及與無麩質飲食指導的協調。在海灣合作理事會（GCC）國家，對三級醫療、專科醫院和先進診斷技術的大量投資正在推動創新胃腸道和自體免疫療法的早期應用，尤其是在慢性病管理計畫完善的地區。歐盟為乳糜瀉治療提供了最完善的環境之一，其監管流程統一，臨床指南完善，藥物安全監測要求嚴格，並且公眾普遍關注無麩質標籤和患者保護。金磚國家構成了一個多元化但具有重要戰略意義的需求環境。巴西、俄羅斯、印度、中國和南非在診斷率、保險報銷體系、小麥消費量和專科醫生資源取得方面存在差異，但總體而言，這些國家對自體免疫疾病的認知不斷提高，藥物研發能力也不斷增強。七國集團（G7）擁有完善的臨床試驗體系、精細的法規結構和高標準的證據生成機制，在乳糜瀉治療藥物的後期療效檢驗和早期臨床應用方面發揮核心作用。北約成員國的醫療保健體系與北美和歐洲的高所得國家高度重合，這些國家擁有健全的醫療供應鏈、高品質的監管體系和跨境研究合作，從而保障了慢性病治療的穩定可及性。對於這些國家而言，最大的機會在於循證安全性、明確的臨床終點、與無麩質飲食的兼容性以及以經濟有效的方式將其整合到乳糜瀉長期護理中。

各國在乳糜瀉治療發展的關鍵見解。

美國是探索乳糜瀉治療的主導地區，這得益於其活躍的臨床試驗、胃腸病學專業知識、患者權益倡導團體以及對預防意外接觸麩質療法的迫切需求。加拿大也有類似的臨床重點，著重於實證治療、明確診斷以及針對持續症狀的安全輔助治療方案。在墨西哥和巴西，隨著胃腸病學服務的改善和公眾對麩質相關疾病認知的加深，人們對該疾病的認知度正在提高，但診斷的一致性、獲得專科醫生診療的機會以及保險報銷仍然是重要的考慮因素。在英國，結構化的臨床指南和對無麩質飲食管理的高度重視，正推動著針對持續症狀和黏膜損傷的治療方案的研發。德國和法國擁有強大的研究體系和專業的醫療保健基礎設施，而義大利和西班牙則擁有完善的臨床專業知識，能夠支持對乳糜瀉的認知、飲食管理體系的建立以及檢驗療法的引入。在俄羅斯，隨著自體免疫疾病專科醫療保健和診斷體系的擴展，新的機會正在湧現，但不同地區的醫療保健服務可近性存在差異。在中國和印度，由於飲食習慣的改變、血清學檢測的普及以及專科醫生意識的提高，乳糜瀉的診斷範圍正在擴大，患者識別成為首要任務，其重要性也隨之提升。日本和韓國擁有先進的醫療保健系統、較高的診斷準確率和強大的臨床研究能力，但疾病認知、檢測實踐和醫生意識仍然影響著治療路徑。澳洲的乳糜瀉患者族群特別活躍，該國擁有完善的診斷標準，並且對無麩質飲食的挑戰有著高度的認知，因此樂於接受那些安全性明確且能改善生活品質的輔助性治療。在所有國家，臨床應用都將取決於明確的診斷、長期安全性數據、可衡量的症狀和組織學改善，以及將這些療法定位為無麩質飲食的「補充」而非「替代」。

為乳糜瀉治療領域的領導企業提供實用建議。

行業領導企業應優先開發能夠解決明確未滿足需求的療法，例如預防意外接觸麩質、治療即使堅持無麩質飲食仍持續存在的症狀、改善粘膜癒合能力以及在專科醫生指導下治療難治性乳糜瀉。臨床計畫應納入檢驗的診斷標準、在適當情況下進行麩質激發試驗、組織學終點指標、患者報告結局、血清學標記以及適用於長期或重複使用的安全性監測。研發人員應將產品設計為無麩質飲食的“輔助療法”而非“替代品”，以符合當前的臨床實踐和患者期望。對患者進行分層，特別是基於HLA類型、疾病活動度、症狀表現型、黏膜損傷、合併自體免疫疾病以及免疫生物計量標記物的分層，至關重要。相關人員應加強與胃腸病學家、註冊營養師、免疫學家、病理學家和患者權益倡導團體的合作，以確保產品在實際應用中的效用以及以患者為中心的治療方案設計。監管策略應強調長期安全性、兒童研發計劃、藥物-食物交互作用評估以及超越實驗室指標的臨床意義改善證據。上市準備工作應包括對基層醫療醫生和專科醫生進行培訓，以減少診斷延誤並改善轉診途徑。數位健康工具可以支持症狀日記、飲食攝取追蹤、遠端監測以及真實世界證據的產生。為確保全球可及性，行業領導者應根據​​區域診斷系統的成熟度、報銷框架、無麩質食品基礎設施以及臨床醫生的專業水平來製定策略。最有效的策略將結合可靠的機制科學、以病人為中心的終點指標、透明的安全性證據以及可操作的、融入終身乳糜瀉管理的方案。

關於乳糜瀉治療藥物的調查方法

本執行摘要採用系統性的二級調查方法撰寫，重點在於與乳糜瀉治療相關的檢驗的臨床、監管、流行病學和科學證據。研究途徑包括分析同行評審的醫學文獻、胃腸病學指南、自體免疫疾病研究、臨床試驗註冊數據、監管科學出版物、診斷標準以及權威的公共衛生資訊來源。治療機制的評估是基於乳糜瀉病理生理學的證據，包括麩質胜肽的免疫抗原性、與HLA-DQ2和HLA-DQ8的關聯、組織轉谷氨醯胺酶活性、腸道滲透性、T細胞介導的免疫反應、黏膜發炎和絨毛萎縮。透過評估醫療保健基礎設施、診斷可及性、專科醫生資源、臨床研究成熟度、對無麩質飲食的認知、監管準備和公共衛生政策，得出區域、群體和國家層面的見解，而不依賴市場規模、市場佔有率或預測假設。本調查方法強調跨多個檢驗資訊來源進行三角驗證，以減少偏差並提高可靠性。研究採用質性解釋方法，識別與推動技術應用、發展障礙以及治療策略定位相關的主題。人工智慧的洞察源於其在藥物發現、臨床試驗最佳化、數位病理學、真實世界數據、生物標記分析和病患監測等領域的成熟應用。所有研究結果均以決策者導向的SEO最佳化格式呈現，避免未經證實的論斷，並剔除公司特定資訊。最終成果是對目前乳糜瀉治療現狀的全面數據支援分析，旨在為策略規劃、研究優先排序和實證產業決策提供支援。

關於乳糜瀉治療未來發展的結論

乳糜瀉的治療在自體免疫胃腸道疾病的管理方面經歷了重大變革，從單純依賴避免麩質飲食發展到以實證醫學為基礎的標靶治療。最具前景的治療方案在於輔助性治療，這些療法可以減輕意外接觸麩質的影響、改善持續性症狀、促進黏膜癒合或調節驅動疾病活動的免疫機制。在診斷、專科護理、臨床試驗基礎設施完善且患者認知水平較高的地區，乳糜瀉的治療準備最為充分，但隨著檢測基礎設施和醫生認知水平的提高，新興地區也具有長期發展潛力。人工智慧（AI）正成為藥物發現、臨床開發、生物標記分析、病理標準化和真實世界監測的關鍵驅動力，但其價值取決於檢驗、數據品質和負責任的應用。能夠將治療創新與患者需求、監管預期、長期安全要求和以飲食為基礎的實用護理相結合的行業領導者，將最有能力推動該領域的發展。成功的關鍵在於展現具有臨床意義的療效，堅持無麩質飲食管理，並在患者、臨床醫生、監管機構和保險公司之間建立信任。隨著科學認知的不斷深入，乳糜瀉的治療領域有望變得更加精準、個人化，並融入全面的自體免疫疾病診療路徑中。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 乳糜瀉治療市場：依藥物類型分類

  • 麩質消化酵素療法
  • 緊密連接改質劑
  • 免疫調節劑
  • 生物製劑

第8章 乳糜瀉治療市場：依分子類型分類

  • 生物製藥
  • 低分子
  • 基於胜肽的藥物

第9章 乳糜瀉治療市場：依給藥途徑分類

  • 注射藥物
  • 口服

第10章：乳糜瀉治療市場：依最終使用者分類

  • 居家照護環境
  • 醫院
  • 專科診所

第11章 乳糜瀉治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 乳糜瀉治療市場：依年齡層別分類

  • 成人
  • 兒童

第13章 乳糜瀉治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 乳糜瀉治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 乳糜瀉治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Ahead Therapeutics SL
  • Amgen Inc.
  • Amneal Pharmaceuticals LLC
  • Anokion SA
  • Barinthus Biotherapeutics plc
  • Biocon Limited
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • Dr. Falk Pharma GmbH
  • Entero Therapeutics Inc.
  • Equillium Inc.
  • F. Hoffmann-La Roche AG
  • Forte Biosciences Inc.
  • GlaxoSmithKline plc
  • Immunic Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Mozart Therapeutics Pty Ltd
  • Parvus Therapeutics Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Theravance Biopharma Inc.
  • Topas Therapeutics GmbH
  • Zedira GmbH
Product Code: MRR-4659C87123C2

The Celiac Disease Drugs Market is projected to grow by USD 2.57 billion at a CAGR of 10.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.29 billion
Estimated Year [2026] USD 1.42 billion
Forecast Year [2032] USD 2.57 billion
CAGR (%) 10.33%

Celiac disease drugs are emerging as a critical therapeutic focus as the limitations of a lifelong gluten-free diet become increasingly evident. Celiac disease is an autoimmune enteropathy triggered by gluten in genetically predisposed individuals, leading to intestinal inflammation, villous atrophy, malabsorption, and systemic complications when inadequately controlled. While strict dietary avoidance remains the standard of care, real-world exposure to hidden gluten, variable adherence, persistent symptoms, and refractory celiac disease have created a clear clinical need for pharmacological interventions. Drug development is concentrated on mechanisms that reduce gluten immunogenicity, block immune activation, protect the intestinal barrier, modulate inflammatory pathways, or induce immune tolerance. Key therapeutic approaches include oral gluten-degrading enzymes, transglutaminase 2 inhibitors, tight junction regulators, cytokine-targeting agents, and antigen-specific immunotherapies. The clinical landscape is shaped by improved serological testing, greater physician awareness, and increased recognition of non-dietary disease burden, including anemia, osteoporosis, infertility, neurological symptoms, and reduced quality of life. Regulatory and clinical momentum is also supported by validated endpoints such as histology, symptom scores, gluten challenge models, and biomarker-based patient stratification. As the celiac disease drugs pipeline advances, stakeholders are prioritizing safety, long-term tolerability, pediatric applicability, and compatibility with dietary management. The sector is transitioning from symptom control toward disease-modifying and exposure-protection strategies designed to address unmet needs in patients with ongoing gluten sensitivity, accidental exposure, or inadequate response to dietary therapy.

Transformative Shifts in the Celiac Disease Drug Landscape

The celiac disease drugs landscape is being reshaped by the shift from diet-only management toward targeted pharmaceutical intervention. Historically, the gluten-free diet served as the sole practical treatment, but clinical evidence shows that some patients continue to experience intestinal injury or symptoms despite reported adherence, often due to cross-contamination, hidden gluten, or incomplete gluten exclusion. This has accelerated interest in adjunct therapies that can reduce mucosal damage and improve daily disease control without replacing dietary discipline. Another transformative shift is the movement from broad anti-inflammatory concepts to mechanism-specific drug design. Developers are increasingly focusing on transglutaminase 2 inhibition to reduce deamidation of gluten peptides, enzymatic detoxification of gluten before immune activation, and intestinal permeability modulation to reduce antigen passage. Immunology-led innovation is also gaining importance, with therapies designed to retrain gluten-specific immune responses and reduce T-cell activation. Clinical development is becoming more patient-centered, emphasizing symptom burden, accidental gluten exposure, histological healing, serologic response, and measurable improvements in quality of life. Diagnostic advances are also influencing the treatment pathway, as serological screening, HLA-DQ2 and HLA-DQ8 association testing, endoscopic confirmation, and biomarker research enable better identification of eligible patients. In parallel, regulators and clinicians are demanding robust evidence of safety because many patients may require chronic or repeated therapy. These shifts are positioning celiac disease drugs as adjunctive, preventive, and potentially disease-modifying solutions within a broader autoimmune gastrointestinal care model.

Cumulative Impact of AI on Celiac Disease Drug Development

Artificial intelligence is influencing celiac disease drug discovery, clinical trial design, patient stratification, and real-world disease management. In early-stage research, AI-enabled protein modeling, immunopeptidomics analysis, and computational screening can help identify gluten epitopes, enzyme candidates, small-molecule inhibitors, and immune-modulating targets relevant to celiac pathophysiology. Machine learning models are increasingly useful for interpreting complex datasets from genomics, transcriptomics, microbiome studies, serology, histopathology, and patient-reported outcomes, enabling more precise understanding of disease heterogeneity. In clinical development, AI can improve trial feasibility by identifying patients with persistent symptoms, confirmed diagnosis, genetic susceptibility, or evidence of active mucosal injury, thereby supporting enrichment strategies and reducing variability. Digital tools also support remote symptom tracking, dietary exposure assessment, adherence monitoring, and detection of patterns associated with accidental gluten ingestion. AI-assisted pathology has potential to standardize villous height, crypt depth, and intraepithelial lymphocyte assessment, improving consistency in histological endpoints. Natural language processing can extract insights from electronic health records to identify underdiagnosed patients, delayed diagnosis patterns, comorbid autoimmune conditions, and care gaps. However, adoption depends on clinically validated algorithms, transparent data governance, bias mitigation, and compliance with privacy regulations. The cumulative impact of artificial intelligence is therefore not limited to faster discovery; it is expanding the evidence infrastructure needed for personalized celiac disease therapeutics, more efficient clinical trials, and better long-term monitoring of treatment response.

Key Regional Insights Across Celiac Disease Drug Adoption

In North America, celiac disease drug development benefits from advanced gastroenterology care pathways, high awareness of autoimmune gastrointestinal disorders, broad availability of tissue transglutaminase IgA testing, active clinical trial infrastructure, and strong patient advocacy supporting adjunct treatment demand. The United States and Canada show substantial readiness for therapies that address accidental gluten exposure and persistent symptoms, particularly where diagnosis is confirmed through standardized serology, duodenal biopsy when indicated, and specialist care. Europe remains highly influential due to established celiac disease guidelines, widespread use of gluten-free dietary standards, strong academic research in immunology and gastroenterology, and structured regulatory expectations for chronic therapies. Countries across Western and Southern Europe have mature diagnostic networks, while variation in reimbursement, gluten-free food support, and nutrition services affects patient access patterns. Asia-Pacific is gaining relevance as awareness and diagnosis improve across China, India, Japan, South Korea, Australia, and ASEAN economies. The region presents diverse clinical dynamics, including historically lower diagnosis rates in parts of Asia, changing wheat consumption patterns, expanding specialty care, and growing use of laboratory diagnostics. Latin America shows increasing recognition of celiac disease, particularly in Brazil and Mexico, supported by expanding gastroenterology services and public attention to gluten-related disorders, though access to specialist diagnosis and confirmatory testing varies by healthcare system. The Middle East is an important emerging region as autoimmune disease awareness rises and GCC healthcare systems invest in specialty diagnostics, tertiary care, and advanced therapeutics. Africa remains comparatively underdiagnosed, but increased availability of serology in urban centers, healthcare expansion, and growing recognition of autoimmune gastrointestinal disease are improving identification of patients who may benefit from future pharmacological options.

Key Group Insights Shaping Celiac Disease Drug Strategies

Across ASEAN, celiac disease drug relevance is tied to improving diagnostic capability, expanding private healthcare networks, and growing recognition that gluten-related autoimmune disease may be underdetected in populations with evolving dietary patterns. Adoption of future therapies will depend on physician education, laboratory access, dietitian availability, and integration with gluten-free dietary counseling. In the GCC, high investment in tertiary care, specialty hospitals, and advanced diagnostics supports early receptivity to innovative gastrointestinal and autoimmune therapies, particularly where chronic disease management programs are well developed. The European Union provides one of the most structured environments for celiac disease therapeutics due to harmonized regulatory pathways, established clinical guidance, strong pharmacovigilance requirements, and widespread public health attention to gluten-free labeling and patient protection. BRICS countries represent heterogeneous but strategically important demand environments: Brazil, Russia, India, China, and South Africa differ in diagnosis rates, reimbursement structures, wheat consumption, and specialist access, yet collectively reflect growing autoimmune disease recognition and expanding pharmaceutical research capabilities. The G7 economies have advanced clinical trial ecosystems, sophisticated regulatory frameworks, and high standards for evidence generation, making them central to late-stage validation and early clinical uptake of celiac disease drugs. NATO member countries overlap substantially with high-income healthcare systems in North America and Europe, where resilient medical supply chains, regulatory quality, and cross-border research collaboration can support stable access to chronic therapies. Across these groups, the strongest opportunities are linked to evidence-backed safety, clear clinical endpoints, compatibility with gluten-free diets, and cost-effective integration into long-term celiac disease care.

Key Country Insights for Celiac Disease Drug Development

The United States is a leading environment for celiac disease drug research due to strong clinical trial activity, gastroenterology specialization, patient advocacy, and high demand for therapies that protect against accidental gluten exposure. Canada shows similar clinical priorities, with emphasis on evidence-based care, diagnostic confirmation, and safe adjunct treatment options for persistent symptoms. Mexico and Brazil are advancing in disease recognition as gastroenterology access improves and public understanding of gluten-related disorders increases, although diagnostic consistency, specialist access, and reimbursement remain important considerations. In the United Kingdom, structured clinical guidance and high awareness of gluten-free management support readiness for therapies that address persistent symptoms or mucosal damage. Germany and France offer strong research and specialty care infrastructure, while Italy and Spain have well-established celiac disease awareness, dietary management systems, and clinical expertise that can support adoption of validated treatments. Russia presents opportunities linked to expanding specialist care and autoimmune disease diagnostics, though access dynamics vary by region. China and India are increasingly important as diagnosis expands with changing dietary patterns, broader serological testing, and improved specialist awareness, making patient identification a central priority. Japan and South Korea combine advanced healthcare systems, high diagnostic quality, and strong clinical research capacity, although disease recognition, testing practices, and physician awareness continue to shape treatment pathways. Australia has a particularly active celiac disease community, strong diagnostic standards, and high awareness of gluten-free dietary challenges, making it receptive to adjunct therapies with clear safety and quality-of-life benefits. Across all countries, clinical uptake will depend on confirmed diagnosis, durable safety data, measurable symptom and histology benefits, and positioning as a complement rather than a substitute for gluten avoidance.

Actionable Recommendations for Celiac Disease Drug Leaders

Industry leaders should prioritize therapies that address clearly defined unmet needs, including protection from accidental gluten exposure, persistent symptoms despite dietary adherence, incomplete mucosal healing, and refractory celiac disease under specialist supervision. Clinical programs should incorporate validated diagnostic criteria, gluten challenge protocols where appropriate, histological endpoints, patient-reported outcomes, serological markers, and safety monitoring suitable for long-term or repeat use. Developers should design products as adjuncts to gluten-free diets rather than replacements, as this aligns with current clinical practice and patient expectations. Investment in patient stratification is essential, particularly around HLA status, disease activity, symptom phenotype, mucosal injury, comorbid autoimmune disease, and immune biomarkers. Stakeholders should strengthen collaboration with gastroenterologists, dietitians, immunologists, pathologists, and patient organizations to ensure real-world relevance and adherence-friendly treatment design. Regulatory strategies should emphasize chronic safety, pediatric development planning, drug-food interaction assessment, and evidence of clinically meaningful improvement beyond laboratory measures. Commercial readiness should include education for primary care and specialists to reduce diagnosis delays and improve referral pathways. Digital health tools can support symptom diaries, dietary exposure tracking, remote monitoring, and real-world evidence generation. For global access, industry leaders should tailor strategies to regional diagnostic maturity, reimbursement frameworks, gluten-free food infrastructure, and clinician familiarity. The most resilient strategies will combine strong mechanistic science, patient-centered endpoints, transparent safety evidence, and practical integration into lifelong celiac disease management.

Research Methodology for Celiac Disease Drug Insights

This executive summary is built using a structured secondary research methodology focused on verified clinical, regulatory, epidemiological, and scientific evidence related to celiac disease therapeutics. The research approach includes analysis of peer-reviewed medical literature, gastroenterology guidelines, autoimmune disease research, clinical trial registries, regulatory science publications, diagnostic standards, and recognized public health sources. Therapeutic mechanisms were assessed through evidence on celiac disease pathophysiology, including gluten peptide immunogenicity, HLA-DQ2 and HLA-DQ8 association, tissue transglutaminase activity, intestinal permeability, T-cell mediated immune response, mucosal inflammation, and villous atrophy. Regional, group, and country insights were developed by evaluating healthcare infrastructure, diagnostic availability, specialist access, clinical research maturity, gluten-free diet awareness, regulatory readiness, and public health policy without using market sizing, market share, or forecasting assumptions. The methodology emphasizes triangulation across multiple validated sources to reduce bias and improve reliability. Qualitative interpretation was applied to identify adoption enablers, development barriers, and therapeutic positioning themes. Artificial intelligence insights were derived from documented applications in drug discovery, trial optimization, digital pathology, real-world evidence, biomarker analysis, and patient monitoring. All findings are presented in an executive, SEO-optimized format for decision-makers while avoiding unsupported claims and excluding company-specific references. The result is a data-backed synthesis of the celiac disease drugs landscape, designed to support strategic planning, research prioritization, and evidence-based industry decision-making.

Conclusion on the Future of Celiac Disease Drugs

Celiac disease drugs represent a pivotal evolution in autoimmune gastrointestinal care, moving beyond exclusive reliance on gluten avoidance toward targeted, evidence-based therapeutic support. The most promising opportunities are concentrated in adjunct treatments that reduce the impact of accidental gluten exposure, improve persistent symptoms, support mucosal healing, or modulate the immune mechanisms driving disease activity. Regional readiness is strongest where diagnosis, specialist care, clinical trial infrastructure, and patient awareness are well developed, while emerging regions offer long-term potential as testing and physician recognition improve. Artificial intelligence is becoming an important accelerator across discovery, clinical development, biomarker analysis, pathology standardization, and real-world monitoring, but its value depends on validation, data quality, and responsible implementation. Industry leaders that align therapeutic innovation with patient needs, regulatory expectations, chronic safety requirements, and practical diet-based care will be best positioned to advance the field. Success will depend on demonstrating clinically meaningful benefits, maintaining compatibility with gluten-free management, and building confidence among patients, clinicians, regulators, and payers. As scientific understanding deepens, the celiac disease drugs landscape is expected to become more targeted, personalized, and integrated into comprehensive autoimmune care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Celiac Disease Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Gluten-Degrading Enzyme Therapies
  • 7.3. Tight Junction Regulators
  • 7.4. Immunomodulators
  • 7.5. Biologics

8. Celiac Disease Drugs Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Biological
  • 8.3. Small Molecule
  • 8.4. Peptide-Based Drugs

9. Celiac Disease Drugs Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral

10. Celiac Disease Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Homecare Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Celiac Disease Drugs Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Celiac Disease Drugs Market, by Age Group

  • 12.1. Introduction
  • 12.2. Adults
  • 12.3. Pediatrics

13. Celiac Disease Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Celiac Disease Drugs Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Celiac Disease Drugs Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Ahead Therapeutics SL
  • 17.3. Amgen Inc.
  • 17.4. Amneal Pharmaceuticals LLC
  • 17.5. Anokion SA
  • 17.6. Barinthus Biotherapeutics plc
  • 17.7. Biocon Limited
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Danaher Corporation
  • 17.10. Dr. Falk Pharma GmbH
  • 17.11. Entero Therapeutics Inc.
  • 17.12. Equillium Inc.
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Forte Biosciences Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Immunic Inc.
  • 17.17. Johnson & Johnson Services Inc.
  • 17.18. Merck & Co. Inc.
  • 17.19. Mozart Therapeutics Pty Ltd
  • 17.20. Parvus Therapeutics Inc.
  • 17.21. Pfizer Inc.
  • 17.22. Recipharm AB
  • 17.23. Sanofi S.A.
  • 17.24. Takeda Pharmaceutical Company Limited
  • 17.25. Teva Pharmaceutical Industries Limited
  • 17.26. Theravance Biopharma Inc.
  • 17.27. Topas Therapeutics GmbH
  • 17.28. Zedira GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLUTEN-DEGRADING ENZYME THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLUTEN-DEGRADING ENZYME THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GLUTEN-DEGRADING ENZYME THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TIGHT JUNCTION REGULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TIGHT JUNCTION REGULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TIGHT JUNCTION REGULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PEPTIDE-BASED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PEPTIDE-BASED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PEPTIDE-BASED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. JAPAN CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. INDIA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. INDIA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. AUSTRALIA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. SOUTH KOREA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 253. GLOBAL CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025